Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy
- PMID: 8854570
- DOI: 10.1016/0925-5710(96)00470-7
Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy
Abstract
The changes of the FVIII binding capacity of vWF after the infusion of FVIII/vWF concentrate was studied in two patients with type 2N vWD, and also during pregnancy in one of them. After infusion of FVIII or DDAVP to the patients, FVIII:C in plasma increased as expected, but it then decreased, with a markedly short half-life, of about 2 h, due to the defect in the FVIII binding capacity of vWF in plasma. However, after infusion of FVIII/vWF concentrate (40 U of FVIII:C/kg), FVIII:C increased, from 4-6 to 100-160 U/dl, more than the expected values, and decreased with the half-life expected. The FVIII binding capacity of vWF in plasma changed in parallel with the concentration of exogenous normal vWF, with a half-life of more than 24 h. During pregnancy, no increase of FVIII:C was observed, although vWF:Ag increased from 40 (before pregnancy) to 90 U/dl in plasma at 35th week of gestation. The FVIII binding capacity of vWF in plasma showed no increase during pregnancy. Accordingly, the administration of FVIII/vWF concentrate to the patient at delivery resulted in adequate hemostasis.
Similar articles
-
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.J Thromb Haemost. 2006 Feb;4(2):357-60. doi: 10.1111/j.1538-7836.2006.01706.x. J Thromb Haemost. 2006. PMID: 16420565 Clinical Trial.
-
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399. Clin Appl Thromb Hemost. 2007. PMID: 17164493 Review.
-
Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.Am J Hematol. 1998 Aug;58(4):311-8. doi: 10.1002/(sici)1096-8652(199808)58:4<311::aid-ajh11>3.0.co;2-a. Am J Hematol. 1998. PMID: 9692396
-
Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.Br J Haematol. 1994 Feb;86(2):333-7. doi: 10.1111/j.1365-2141.1994.tb04735.x. Br J Haematol. 1994. PMID: 8199023
-
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506358 Review.
Cited by
-
Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.Intern Med. 2017;56(13):1719-1723. doi: 10.2169/internalmedicine.56.7487. Epub 2017 Jul 1. Intern Med. 2017. PMID: 28674365 Free PMC article.
-
Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.Int J Hematol. 2020 Mar;111(3):369-377. doi: 10.1007/s12185-019-02782-z. Epub 2019 Nov 18. Int J Hematol. 2020. PMID: 31741138
MeSH terms
Substances
LinkOut - more resources
Miscellaneous